Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

After VERVE-102 showed the ability to lower LDL-C and PCSK9 in the Heart-2 trial, the firm said it will advance the therapy to a Phase II study later this year.

After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

NEW YORK – The US Food and Drug Administration on Thursday granted full approval to Bayer's TRK inhibitor Vitrakvi (larotrectinib) for treating adult and pediatric patients with previously treated ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

NEW YORK – Amylyx Pharmaceuticals announced this week that it has dosed the first amyotrophic lateral sclerosis (AML) patient with its investigational antisense oligonucleotide therapy (ASO), AMX0114, ...